<DOC>
	<DOCNO>NCT00521560</DOCNO>
	<brief_summary>Phase II Study Concomitant High-Dose Radio-Immuno- Chemotherapy simultaneous application Zevalin BEAM follow autologous peripheral stem cell transplantation relapse refractory CD 20+ Non-Hodgkin 's lymphoma</brief_summary>
	<brief_title>A Study Zevalin Simultaneous Application BEAM High-dose Chemotherapy Followed Autologous Stem Cell Transplantation Refractory Relapsed Aggressive Non-Hodgkin Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Age : 18 65 year Risk group : 1 ) Progression primary therapy 2 ) Initial subsequent relapse Histology : Diagnosis relapse aggressive nonHodgkin lymphoma , whenever possible confirm excision biopsy lymph node sufficiently large biopsy extranodal site lymph node lesion present . The expression CD20 antigen must demonstrate primary lesion relapse . Specifically , follow entity treat study : BNHL : Grade III B follicular lymphoma Diffuse Bcell lymphoma centroblastic immunoblastic plasmoblastic anaplasticlargecell Tcell rich Bcell lymphoma Primary effusion lymphoma Intravascular Bcell lymphoma Primary mediastinal Bcell lymphoma Mantle cell lymphoma , blastoid Variants Burkitt 's lymphoma Aggressive marginal zone lymphoma ( monocytoid ) General condition : General condition ECOG 03 ( Karnofsky : 40 100 % ) ; definition see Annex 14.10 Presence declaration participation center patient 's write consent form Prior mediastinal extensive abdominal irradiation Prior highdose therapy autologous stem cell transplantation Impairment renal function ( creatinine &gt; 2.5 mg/dL , creatinine clearance &lt; 20 mL/min ) Impairment hepatic function ( bilirubin &gt; 2.0 mg/dL , cholinesterase [ CHE ] &lt; 2000 U/L ) Impairment pulmonary function ( transfer lung factor CO [ TLCO ] &lt; 50 % , forced expiratory volume 1 sec [ FEV1 ] &lt; 60 % , vital capacity [ VC ] &lt; 60 % ) Relevant deterioration organ function salvage therapy Failure stem cell mobilization Active viral hepatitis HIV infection Other active conclusively curatively treated malignoma Severe concomitant psychiatric illness suspect lack patient compliance Pregnancy unreliable contraception Highly dynamic progress lymphoma ( lactate dehydrogenase [ LDH ] &gt; 1.5 x upper limit normal [ ULN ] ) salvage therapy immediately prior radioimmunotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>High-Dose Radio-Immuno- Chemotherapy</keyword>
	<keyword>stem cell transplantation</keyword>
	<keyword>90Y-Ibritumomab-Tiuxetan</keyword>
</DOC>